In This Section

Pro-Psychotic Effects of Drugs of Abuse

Sunday April 22, 2018

3:30 pm - 6:00 pm

Room 16B
Sponsored by the Division for Behavioral Pharmacology (BEH)
Co-sponsored by the Division for Drug Discovery and Development (DDD)
Co-sponsored by the Division for Pharmacology Education (DPE)

Chair :

Michael Wood
Circuit Therapeutics, Inc

Michael Berquist
University of Arkansas for Medical Sciences

Chronic abuse of drugs from various pharmacological classes can produce psychoses that are indistinguishable from symptoms associated with schizophrenia. A well-characterized example of this is amphetamine-induced psychotic disorder. In laboratory settings, the use of pharmacologically-induced models of psychosis has greatly improved our understanding of psychosis and aided in identifying mechanisms beyond dopamine antagonism that may increase antipsychotic efficacy. This symposium will address the role of serotonergic, glutamatergic, and cannabinergic neurotransmitter systems in mediating or attenuating aspects of psychosis, and provide a current review of pharmacologically-induced models of psychosis.

Beyond Dopamine: Neuropharmacology of Atypical Antipsychotics
Michael Wood - Circuit Therapeutics, Inc

Becoming Unglued: Glutamate Dysfunction and Psychosis
Bita Moghaddam - Oregon Health & Sciences University

A Trip Down the Rabbit Hole: Hallucinogens and Psychosis
Susan Powell - University of California, San Diego

Reefer Madness: Insights from Cannabinoid-Induced Psychosis
Patrick Skosnik - Yale University

There’s a Cat in the Colony Room: Modeling Psychosis in Rodents
Michael Berquist - University of Arkansas for Medical Sciences

Thank you to our Annual Meeting partners:

University of Florida
Wake Forest University
Washington State University College of Pharmacy and Pharmaceutical Sciences
University of Wisconsin Molecular and Cellular Pharmacology Training Program
UT Health San Antonio
University of Minnesota

Emory University Pharmacology

PR & P
University of Michigan Medical School Pharmacology